BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report)'s stock price was up 4.2% during trading on Friday . The company traded as high as $27.20 and last traded at $27.20. Approximately 48,816 shares changed hands during trading, a decline of 87% from the average daily volume of 382,486 shares. The stock had previously closed at $26.11.
Wall Street Analysts Forecast Growth
BLFS has been the subject of a number of research reports. Benchmark reaffirmed a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday. HC Wainwright dropped their target price on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Monday, November 18th. TD Cowen increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. KeyCorp lifted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a report on Friday, December 13th. Finally, Craig Hallum increased their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat, BioLife Solutions presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.00.
Read Our Latest Analysis on BLFS
BioLife Solutions Price Performance
The stock's 50 day moving average is $24.86 and its two-hundred day moving average is $23.68. The stock has a market capitalization of $1.27 billion, a PE ratio of -25.84 and a beta of 1.91. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.
Insider Buying and Selling at BioLife Solutions
In related news, EVP Aby J. Mathew sold 7,604 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the completion of the transaction, the executive vice president now owns 276,315 shares in the company, valued at approximately $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 64,259 shares of company stock valued at $1,424,708. Insiders own 2.20% of the company's stock.
Institutional Trading of BioLife Solutions
A number of hedge funds and other institutional investors have recently bought and sold shares of BLFS. Mark Sheptoff Financial Planning LLC purchased a new position in shares of BioLife Solutions in the 3rd quarter valued at about $28,000. Isthmus Partners LLC raised its holdings in BioLife Solutions by 34.4% during the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 42,265 shares in the last quarter. 1620 Investment Advisors Inc. purchased a new stake in shares of BioLife Solutions during the 2nd quarter worth approximately $35,000. Quest Partners LLC acquired a new position in shares of BioLife Solutions in the 3rd quarter valued at $57,000. Finally, GAMMA Investing LLC boosted its holdings in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock valued at $83,000 after buying an additional 748 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
See Also
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
